Peripheral edema from MET inhibitors like capmatinib or tepotinib is cumulative and unavoidable over long-term treatment. Dr. Liu notes that diuretics merely elevate creatinine and compression stockings simply displace fluid. Instead of continuing until disease progression, clinicians should reduce doses and implement temporary treatment breaks until swelling recedes to an acceptable baseline, resuming therapy before tumor progression occurs.
Clinicians often avoid maintenance lurbinectedin in extensive-stage small cell lung cancer to give patients a chemotherapy holiday. Dr. Liu argues this holiday is an oncology construct patients are unaware of. By framing the transition from the start—stepping down from a three-drug, three-day regimen to a two-drug, single-day regimen—oncologists can preserve the proven overall survival benefit before high post-progression attrition prevents second-line therapy.
Target expression does not cleanly correlate with antibody-drug conjugate activity because receptor internalization matters more than surface presence alone. In lung cancer, HER2 tyrosine kinase domain mutations cause the receptor to internalize much faster than the native receptor, driving more efficient trafficking of the deruxtecan payload into the cell. Consequently, HER2 mutation status is a vastly superior predictor of T-DXD efficacy compared to HER2 immunohistochemistry overexpression.
Datopotamab deruxtecan causes stomatitis in about 60% of lung cancer patients, with grade 3 cases near 10%. Although the standard dose is 6 mg/kg, early trial data showed 4 mg/kg provides very similar antitumor efficacy. Clinicians should maintain a low threshold to dose-reduce patients to 4 mg/kg when oral toxicity arises, alongside routine oral dexamethasone rinses and cryotherapy.
Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.
T-cell engagers such as tarlatamab are inherently designed for low disease burden, performing best when there is a high drug-to-target ratio. Because antibody-drug conjugates like I-DXD yield high disease control and deep responses, sequencing or pairing ADCs to debulk bulky small cell lung cancer creates an optimal clinical setting for subsequent T-cell engager efficacy.
Despite significant interest in small cell lung cancer transcriptional subtypes, Dr. Liu warns clinicians against using them for treatment stratification. Unlike fixed genomic mutations, these transcriptional profiles are dynamic, plastic states that fluctuate and transition over time. Because the cancer shifts between subtypes throughout progression, they currently fail to serve as stable, predictive clinical biomarkers.
In HER2-mutant non-small cell lung cancer, the DESTINY-Lung02 trial established that starting trastuzumab deruxtecan at 5.4 mg/kg instead of 6.4 mg/kg cuts interstitial lung disease rates from 32% down to 15%. Because antitumor efficacy and response rates remain equivalent between both doses, 5.4 mg/kg represents the necessary standard to minimize potentially fatal pulmonary toxicity.